Published Date: 16 May 2025
Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco Vizeacoumar (Ph.D.) and Dr. Andrew Freywald (Ph.D.) with USask and the Saskatchewan Cancer Agency.
Read Full NewsTelemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.
A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.
Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.
A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.
1.
Breast cancer screening in women's 40s can save lives, study says
2.
Researchers publish action plan to address appendiceal cancer enigmas
3.
Novel probes to label macrophages associated with cancer progression using a selective dye
4.
Scholastic performance is a key concern for young cancer patients, study finds
5.
Updates from the 2022 WHO classification of kidney epithelial tumors
1.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
2.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies
5.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation